OPT

1.83%

80.5¢ opthea limited

Opthea Q&A Sep 2024 Update, page-26

First 26 Last

willxue123

457 Posts.

04/09/24

13:52

Post #: 75525129

Originally posted by FreeFromStyle: ↑

Year/Month Event/Activity
1 1984 Company Founded - Opthea was originally established as Circadian Technologies Limited.
2 2015 Company Rebranding - Opthea shifted its focus primarily to developing treatments for retinal diseases such as Wet AMD.
3 2018-2020 Phase 1/2a Trials (Sozinibercept) - Early clinical trials began to assess safety and efficacy in combination with anti-VEGF therapies.
4 2021-2022 Phase 2b Trials - Enrolled 366 Wet AMD patients. Top-line data: +5.7 letter improvement in BCVA at 24 weeks.
5 September 2023 Capital Raising - Issued 160 million shares to institutional investors and 16 million shares to retail investors, raising A$82 million.
6 December 2023 Amended DFA with Carlyle/Abingworth - Provided US$170 million in non-equity funding.
7 February 2024 Phase 3 COAST Trial Enrollment Complete - 998 patients enrolled.
8 May 2024 Phase 3 SHORE Trial Enrollment Complete - 986 patients enrolled.
9 June 2024 Capital Raising - Issued shares to raise A$171.5 million, with an additional retail component raising A$55.9 million.
10 April 2025 Top-line Data (COAST Trial) - Expected release of 52-week safety and efficacy results.
11 July-August 2025 Top-line Data (SHORE Trial) - Expected release of 52-week safety and efficacy results.
12 September 2025 OPTOA Options Expiry - OPTOA options (A$0.80 exercise price) expire.
13 April 2026 12-Month Safety Review (COAST Trial) - Long-term safety review of COAST trial.
14 June 2026 OPTOB Options Expiry - OPTOB options (A$1.00 exercise price) expire.
15 July-August 2026 12-Month Safety Review (SHORE Trial) - Long-term safety review of SHORE trial.
16 Mid to Late 2026 FDA Approval (Potential) - Sozinibercept could be approved for U.S. market entry.
17 Mid to Late 2026 Capital Raising (for Commercialization) - Expected capital raise to fund commercialization.
18 Late 2026 - Early 2027 Commercialization (Sozinibercept) - Sozinibercept could enter the U.S. market following FDA approval.

Thanks, Pigrace! While I did build a knowledge base using GPT with public info on Opthea, the validation were done by me so got the date wrong.I've now improved the wording and included the long-term safety review, which happens 12 months after the topline results. I’ve also updated the SHORE topline readout timeline to allow an extra month for data analysis.Are there any other key dates that are wrong or missing?
Expand
I think if fully exercise the options, probably no longer need CR.

OPT Price at posting: 54.8¢ Sentiment: Hold Disclosure: Held

1 Upvote

0 Great analysis

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BMO

Bastion sees echoes of its Gyttorp Cu and REE mineralisation at new Swedish tenements

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NHF

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Trump is President Again: What Does This Mean for Crypto?

There are more pages in this discussion • 17 more messages in this thread...

First 26 Last

Add OPT (ASX) to my watchlist

(20min delay)
Last 80.5¢		Change -0.015(1.83%)		Mkt cap ! $997.1M

Open	High	Low	Value	Volume
81.5¢	83.0¢	80.0¢	$185.3K	228.2K

Buyers (Bids)

No.	Vol.	Price($)
9	74566	80.0¢

Sellers (Offers)

Price($)	Vol.	No.
80.5¢	23030	14

View Market Depth

No.	Vol.	Price($)
9	74566	0.800
6	33052	0.795
12	152543	0.790
5	23575	0.785
6	58345	0.780

Price($)	Vol.	No.
0.805	23030	14
0.810	14891	8
0.815	9344	8
0.820	139116	7
0.830	249714	4

Last trade - 12.02pm 12/11/2024 (20 minute delay)

OPT (ASX) Chart

Opthea Q&A Sep 2024 Update, page-26

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bastion sees echoes of its Gyttorp Cu and REE mineralisation at new Swedish tenements

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Trump is President Again: What Does This Mean for Crypto?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	Year/Month	Event/Activity
1	1984	Company Founded - Opthea was originally established as Circadian Technologies Limited.
2	2015	Company Rebranding - Opthea shifted its focus primarily to developing treatments for retinal diseases such as Wet AMD.
3	2018-2020	Phase 1/2a Trials (Sozinibercept) - Early clinical trials began to assess safety and efficacy in combination with anti-VEGF therapies.
4	2021-2022	Phase 2b Trials - Enrolled 366 Wet AMD patients. Top-line data: +5.7 letter improvement in BCVA at 24 weeks.
5	September 2023	Capital Raising - Issued 160 million shares to institutional investors and 16 million shares to retail investors, raising A$82 million.
6	December 2023	Amended DFA with Carlyle/Abingworth - Provided US$170 million in non-equity funding.
7	February 2024	Phase 3 COAST Trial Enrollment Complete - 998 patients enrolled.
8	May 2024	Phase 3 SHORE Trial Enrollment Complete - 986 patients enrolled.
9	June 2024	Capital Raising - Issued shares to raise A$171.5 million, with an additional retail component raising A$55.9 million.
10	April 2025	Top-line Data (COAST Trial) - Expected release of 52-week safety and efficacy results.
11	July-August 2025	Top-line Data (SHORE Trial) - Expected release of 52-week safety and efficacy results.
12	September 2025	OPTOA Options Expiry - OPTOA options (A$0.80 exercise price) expire.
13	April 2026	12-Month Safety Review (COAST Trial) - Long-term safety review of COAST trial.
14	June 2026	OPTOB Options Expiry - OPTOB options (A$1.00 exercise price) expire.
15	July-August 2026	12-Month Safety Review (SHORE Trial) - Long-term safety review of SHORE trial.
16	Mid to Late 2026	FDA Approval (Potential) - Sozinibercept could be approved for U.S. market entry.
17	Mid to Late 2026	Capital Raising (for Commercialization) - Expected capital raise to fund commercialization.
18	Late 2026 - Early 2027	Commercialization (Sozinibercept) - Sozinibercept could enter the U.S. market following FDA approval.

Opthea Q&A Sep 2024 Update, page-26

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bastion sees echoes of its Gyttorp Cu and REE mineralisation at new Swedish tenements

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Trump is President Again: What Does This Mean for Crypto?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News